Lam Research CEO Timothy Archer sells $7.1M in company stock

Timothy Archer, President and CEO of Lam Research Corp (NASDAQ:LRCX), sold 31,400 shares of the company’s common stock on October 23, 2026, for a total value of $7,128,428. The shares were sold at a price of $227.02 each. The stock has since risen to $239.54, though it experienced a sharp 15.5% decline over the past week amid broader market volatility.

The sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Archer adopted on February 24, 2026.

Prior to the sale, Mr. Archer acquired an equal number of shares, 31,400, through the exercise of employee stock options. These options were exercised at a price of $30.033 per share, totaling $943,036. The stock options became exercisable in three equal installments on March 2, 2021, March 2, 2022, and March 2, 2023.

Following these transactions, Mr. Archer directly holds 1,075,966 shares of Lam Research common stock. This amount includes shares subject to unvested restricted stock units. Additionally, Mr. Archer indirectly holds 48,025.72 shares through a 401(k) and 5,670.002 shares through a spouse’s 401(k).The semiconductor equipment maker maintains strong financial fundamentals, with a P/E ratio of 35.72 and a PEG ratio of 0.71, suggesting attractive valuation relative to growth. According to InvestingPro analysis, the stock is trading near its Fair Value. Investors can access the comprehensive Pro Research Report for LRCX, along with 10+ additional ProTips, on the platform.

In other recent news, Lam Research reported impressive first-quarter fiscal 2027 results, with revenue reaching $8.22 billion and earnings per share of $2.20, surpassing analyst expectations of $8.13 billion in revenue and $2.19 per share. The company achieved record revenue, gross margin, and operating margin, with systems revenue seeing significant growth. However, supply chain constraints were noted as a limiting factor for future projections. Bernstein SocGen Group, BofA Securities, and Needham all adjusted their price targets for Lam Research, citing various factors such as supply constraints and valuation resets, but maintained positive ratings on the stock. Bernstein lowered its target to $350, BofA to $345, and Needham to $290. Despite the positive earnings report, Lam Research’s shares experienced a decline in after-hours trading. The company also highlighted its long-term growth prospects, particularly in Aether-related revenue, which is expected to reach approximately $2.5 billion by the end of the decade.